Johan Wedell-Wedellsborg net worth and biography

Johan Wedell-Wedellsborg Biography and Net Worth

Director of Y-mAbs Therapeutics

Johan Wedell-Wedellsborg is Owner and Chairman of the Board of Weco Group, which he took over in 2001. Weco Group is primarily a Ship Owning Company, which operates within the product tanker segment, multi-purpose vessels, RORO line and handy size bulk carriers. The shipping part of Weco Group records annual revenue of approximately $200 million. Besides shipping, Weco Group also is involved in realty investments, financial services, art and biotech. Wedell-Wedellsborg is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.

What is Johan Wedell-Wedellsborg's net worth?: The estimated net worth of Johan Wedell-Wedellsborg is at least $20.89 million as of November 27th, 2023. Mr. Wedell-Wedellsborg owns 4,342,721 shares of Y-mAbs Therapeutics stock worth more than $20,888,488 as of March 30th. This net worth estimate does not reflect any other assets that Mr. Wedell-Wedellsborg may own. Learn More about Johan Wedell-Wedellsborg's net worth.
How do I contact Johan Wedell-Wedellsborg?: The corporate mailing address for Mr. Wedell-Wedellsborg and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at info@ymabs.com. Learn More on Johan Wedell-Wedellsborg's contact information.
Has Johan Wedell-Wedellsborg been buying or selling shares of Y-mAbs Therapeutics?: Johan Wedell-Wedellsborg has not been actively trading shares of Y-mAbs Therapeutics during the past quarter. Most recently, on Monday, November 27th, Johan Wedell-Wedellsborg bought 62,516 shares of Y-mAbs Therapeutics stock. The stock was acquired at an average cost of $5.49 per share, with a total value of $343,212.84. Following the completion of the transaction, the director now directly owns 4,342,721 shares of the company's stock, valued at $23,841,538.29. Learn More on Johan Wedell-Wedellsborg's trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 214,171 shares worth more than $2,618,929.67. The most recent insider tranaction occured on March, 7th when CEO Michael J Rossi sold 3,917 shares worth more than $20,368.40. Insiders at Y-mAbs Therapeutics own 22.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 3/7/2025.

Johan Wedell-Wedellsborg Insider Trading History at Y-mAbs Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2023	Buy	62,516	$5.49	$343,212.84	4,342,721
5/15/2023	Buy	101,740	$9.65	$981,791.00	4,280,205
6/3/2021	Sell	30,666	$33.19	$1,017,804.54	4,415,935
6/1/2021	Sell	6,864	$35.57	$244,152.48	4,453,465
5/28/2021	Sell	25,000	$36.34	$908,500.00	4,453,465
9/6/2019	Sell	17,243	$27.00	$465,561.00
8/30/2019	Sell	89,166	$26.58	$2,370,032.28
8/28/2019	Sell	49,357	$27.08	$1,336,587.56
8/21/2019	Sell	168,244	$27.57	$4,638,487.08

Johan Wedell-Wedellsborg Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $4.81

$4.73

$5.25

50 Day Range

MA: $5.58

$4.54

$6.42

2 Week Range

Now: $4.81

$4.25

$17.78

Volume

164,220 shs

Average Volume

333,807 shs

Market Capitalization

$217.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65